CAN FITE BIOPHARMA LTD-ADR (CANF)
US13471N3008 - ADR
Taking everything into account, CANF scores 3 out of 10 in our fundamental rating. CANF was compared to 587 industry peers in the Biotechnology industry. The financial health of CANF is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CANF is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CANF has reported negative net income.
CANF had a negative operating cash flow in the past year.
In the past 5 years CANF always reported negative net income.
CANF had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -76.42%, CANF is not doing good in the industry: 70.09% of the companies in the same industry are doing better.
CANF has a Return On Equity of -122.28%. This is in the lower half of the industry: CANF underperforms 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.42% | ||
| ROE | -122.28% | ||
| ROIC | N/A |
ROA(3y)-87.03%
ROA(5y)-114.94%
ROE(3y)-151.83%
ROE(5y)-244.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CANF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CANF has been increased compared to 1 year ago.
The number of shares outstanding for CANF has been increased compared to 5 years ago.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -22.23, we must say that CANF is in the distress zone and has some risk of bankruptcy.
CANF has a worse Altman-Z score (-22.23) than 88.38% of its industry peers.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.23 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
CANF has a Current Ratio of 4.90. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CANF (4.90) is comparable to the rest of the industry.
A Quick Ratio of 4.90 indicates that CANF has no problem at all paying its short term obligations.
With a Quick ratio value of 4.90, CANF perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.9 |
3. Growth
3.1 Past
CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.54%, which is quite impressive.
CANF shows a decrease in Revenue. In the last year, the revenue decreased by -8.27%.
CANF shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.92% yearly.
EPS 1Y (TTM)50.54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q69.1%
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y-27.92%
Revenue growth Q2Q-21.32%
3.2 Future
CANF is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.38% yearly.
Based on estimates for the next years, CANF will show a very strong growth in Revenue. The Revenue will grow by 97.60% on average per year.
EPS Next Y15.09%
EPS Next 2Y9.76%
EPS Next 3Y6.38%
EPS Next 5YN/A
Revenue Next Year433.92%
Revenue Next 2Y91%
Revenue Next 3Y97.6%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CANF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CANF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.76%
EPS Next 3Y6.38%
5. Dividend
5.1 Amount
No dividends for CANF!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CAN FITE BIOPHARMA LTD-ADR
NYSEARCA:CANF (5/6/2024, 5:40:01 PM)
2.11
+0.02 (+0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.53M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.42% | ||
| ROE | -122.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.9 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50.54%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y15.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y